FDA Panel Meets Today on Vertex HepC Drug

Xconomy Boston — 

Vertex Pharmaceuticals (NASDAQ:VRTX) faces a test today for its experimental drug for hepatitis C virus, telaprevir, as the FDA Antiviral Drugs Advisory Committee meets today in Silver Springs, MD, to review the firm’s application for approval of the treatment. NASDAQ has halted trading of the Cambridge, MA-based firm’s common stock today, according to Vertex. Yesterday the same FDA panel voted unanimously in favor of recommending approval of Whitehouse Station, NJ-based Merck & Co.’s (NYSE:MRK) hepatitis C pill boceprevir, and many industry watchers are expecting Vertex to have similar success today. An FDA staff review released on Tuesday gave Vertex’s hepatitis C pill some high marks as a treatment for the liver disease.

By posting a comment, you agree to our terms and conditions.

Comments are closed.